Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.11.22 (cdc2)
 8,319 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Within the last years significant improvements have been achieved in early and metastatic breast cancer treatment by innovative targeted therapies and new drug combinations. GnRH-analogues have been confirmed as an important part of endocrine treatment in premenopausal patients. Endocrine based strategies including CDK-4/6-Inhibitors substantially improve progression-free survival in metastatic patients. For patients with HER2-positive disease the addition of Pertuzumab to Trastuzumab in combination with chemotherapy has achieved a significant improvement in anti-HER2 therapy in early as well as metastatic breast cancer. For triple-negative disease chemotherapy is still the mainstay of treatment. Immune checkpoint inhibitors represent promising strategies in this cohort, which are currently being evaluated in clinical trials. PARP inhibitors will be available as innovative treatment concept in BRCA1/2 mutation carriers.
 ...
PMID:[Systemic Treatment of Early and Metastatic Breast Cancer]. 3050 53